45511-81-7

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(AMINOMETHYL)CYCLOPENTANOL is used as a precursor for the development of biologically active molecules, contributing to the creation of new pharmaceuticals due to its unique structural properties and reactivity.
Used in Organic Chemistry:
1-(AMINOMETHYL)CYCLOPENTANOL is used as a reagent in various chemical reactions, facilitating the synthesis of a wide range of organic compounds.
Used as a Chiral Auxiliary in Asymmetric Synthesis:
1-(AMINOMETHYL)CYCLOPENTANOL is used to induce chirality in chemical reactions, aiding in the production of enantiomerically pure compounds, which is crucial for the development of effective and selective drugs.
Used in Medicinal Chemistry:
1-(AMINOMETHYL)CYCLOPENTANOL is used as a starting material for the synthesis of complex organic molecules with potential therapeutic applications, enhancing the discovery and innovation of new medicines.

InChI:InChI=1/C6H13NO/c7-5-6(8)3-1-2-4-6/h8H,1-5,7H2

Upstream product

• 73825-69-1 acetic acid-(1-cyano-cyclopentyl ester) 
• 25438-35-1 1-[(trimethylsilyl)oxy]cyclopentanecarbonitrile 
• 120-92-3 cyclopentanone 
• 72936-38-0 1-(nitromethyl)cyclopentanol 
• 5117-85-1 1-hydroxycyclopentanecarbonitrile 

Downstream Products

• 108-94-1 cyclohexanone 
• 130643-07-1 6-oxa-9-aza-spiro[4.5]decane 
• 1227808-83-4 C₁₇H₁₇ClFN₃O₂ 

Relevant academic research and scientific papers

PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS

Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS

The present application relates to thiazolylidene containing compounds of formula (I) wherein R1, R2, R3, R4, L2 and A are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Sulfone substituted imidazo ring ethers

Imidazo ring compounds (e.g., imidazoquinolines, 6,7,8,9-tetrahydroimidazoquinolines, imidazonaphthyridines, and 6,7,8,9-tetrahydroimidazonaphthyridines) with a sulfide-, sulfinyl-, or sulfonyl-containing ether substituent at the 1-position, pharmaceutica

SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES

Imidazo-quinoline, -pyridine, and -naphthyridine ring systems (particularly quinolines, tetrahydroquinolines, pyridines, [1,5]naphthyridines, [1,5]tetrahydronaphthyridines) substituted at the 1-position with a cyclic substituent, pharmaceutical compositions containing the compounds, methods of making these compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

ARYL SUBSTITUTED IMIDAZONAPHTHYRIDINES

Imidazonaphthyridine ring systems substituted with an aryl substituent, pharmaceutical compositions containing the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of

Importance of the Aromatic Ring in Andrenergic Amines. 5. Nonaromatic Analogues of Phenylethanolamine as Inhibitors of Phenylethanolamine N-Methyltransferase: Role of Hydrophobic and Steric Interactions

The synthesis of five classes of nonaromatic analogues of β-phenylethanolamine and an evaluation of their inhibitory potency (IC50) for phenylethanolamine N-methyltransferase (PNMT) are described.The key intermediates for the synthesis of the ethanolamines were the appropriate aldehydes or ketones.The aldehydes 11a (cyclobutyl) and 13a (cycloheptyl) of type A were prepared from the correspondingacids by reduction of the acid to the alcohol with lithium aluminum hydride and oxidation of the alcohol to the aldehyde with pyridinium chlorochromate (PCC).The aldehydes 15a (cycloundecyl) and 41a (adamantyl) of type A were prepared by oxidation of the corresponding alcohols with PCC.The first reported synthesis of cyclononanecarboxaldehyde (type A, 14a) is described.This aldehyde was prepared via a multistep route beginning with a Favorskii rearrangement of 2-bromocyclodecanone to cyclononanecarboxylic acid.The acid was reduced with lithium aluminum hydride to the corresponding alcohol, which was subsequently oxidized to the aldehyde with PCC.The aldehydes or ketones were converted (with trimethylsilyl cyanide) into their cyanohydrin ethers, which were subsequently reduced to the desired ethanolamine with lithium aluminum hydride.The ethanolamines were tested as inhibitors (LCEC assay) of PNMT.The most potent inhibitors were the type A compounds 8 (cyclooctyl), 13c (cycloheptyl), 14c (cyclononyl), and 15c (cycloundecyl) and the type D compounds 26c (cyclononyl) and 27c (cycloundecyl) with IC50 values from 6 to 17 μM.It isconcluded that the binding site of PNMT accepts hydrophobic groups of an optimal length (ca. 6.4 Angstroem) and width (ca. 2.5 Angstroem) and has a significant height restriction for the hydrophobic group.The ethanolamine side chain prefers to lie away from and in the longitudinal axis of the hydrophobic group.An ethanolamine side chain attached to a cycloalkyl ring of n carbon atoms (types A and D) is almost always considerably more potent at inhibiting PNMT than the open-chain compounds of n total carbon atoms (types B, C, and E).

Labelling of a new hypolipaemic agent with carbon 14, preparation of 1,1 bis[4 (1 carboxy 1 methylpropoxy)phenyl]cyclohexane 2 14C

1,1 Bis[4 (1 carboxy 1 methylpropoxy)phenyl] cyclohexane (S 8527) (I), a new hypolipemic agent, was labelled as C 2 with carbon 14 for the use of metabolic studies. Cyclohexane 2 14C which was prepared from potassium cyanide 14C was condensed with phenol to produce 1,1 bis(4 hydroxyphenyl)cyclohexane 2 14C (VI). Condensation of VI with ethyl methyl ketone and chloroform under a strong base (potassium hydroxide) gave S 8527 2 14C (I). A total of 3.11 mCi of pure S 8527 2 14C (I) was obtained, representing a 12% radiochemical yield from potassium cyanide 14C. Furthermore, a new radioactive by product was isolated and elucidated its structure as X.